Banque Cantonale Vaudoise Has $3.22 Million Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Banque Cantonale Vaudoise raised its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 108.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,823 shares of the medical equipment provider’s stock after buying an additional 15,535 shares during the period. Banque Cantonale Vaudoise’s holdings in Zimmer Biomet were worth $3,219,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of ZBH. Gradient Investments LLC increased its holdings in Zimmer Biomet by 17.3% during the 2nd quarter. Gradient Investments LLC now owns 130,350 shares of the medical equipment provider’s stock valued at $14,147,000 after purchasing an additional 19,224 shares in the last quarter. National Pension Service lifted its position in Zimmer Biomet by 3.8% during the 3rd quarter. National Pension Service now owns 369,547 shares of the medical equipment provider’s stock worth $39,893,000 after buying an additional 13,612 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in Zimmer Biomet by 7.3% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 229,233 shares of the medical equipment provider’s stock worth $30,265,000 after acquiring an additional 15,548 shares during the last quarter. Swedbank AB acquired a new stake in Zimmer Biomet in the 1st quarter valued at about $2,740,000. Finally, River Global Investors LLP raised its stake in shares of Zimmer Biomet by 31.3% in the third quarter. River Global Investors LLP now owns 21,084 shares of the medical equipment provider’s stock worth $2,276,000 after acquiring an additional 5,030 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Down 1.8 %

Shares of ZBH stock opened at $110.95 on Wednesday. The company has a market capitalization of $22.09 billion, a price-to-earnings ratio of 21.09, a P/E/G ratio of 2.08 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90. The firm has a fifty day moving average of $106.56 and a 200-day moving average of $109.86. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.74. The firm had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter last year, the business posted $1.65 EPS. As a group, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date of this dividend was Monday, September 30th. Zimmer Biomet’s dividend payout ratio is presently 18.25%.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Wolfe Research assumed coverage on shares of Zimmer Biomet in a report on Tuesday, September 10th. They issued a “peer perform” rating for the company. UBS Group dropped their target price on Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating for the company in a research report on Thursday, August 8th. Raymond James decreased their price target on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. JPMorgan Chase & Co. lowered their price objective on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a research report on Monday, September 16th. Finally, Truist Financial raised their target price on shares of Zimmer Biomet from $112.00 to $117.00 and gave the company a “hold” rating in a research note on Friday, November 1st. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $123.22.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.